Moreover, anti-CD20 pharmacological agents have been shown to eliminate not only CD20-bearing B-cells but also specific CD3+CD20dim, CD8+CD20+ and other T-cell subsets [32,33,34,84] with an evidently pathogenic potential in the context of MS. Here, CD8A is linked to myeloid sarcoma.